TY - JOUR
T1 - Site- and allele-specific polycomb dysregulation in T-cell leukaemia
AU - Navarro, Jean Marc
AU - Touzart, Aurore
AU - Pradel, Lydie C.
AU - Loosveld, Marie
AU - Koubi, Myriam
AU - Fenouil, Romain
AU - Le Noir, Sandrine
AU - Maqbool, Muhammad Ahmad
AU - Morgado, Ester
AU - Gregoire, Claude
AU - Jaeger, Sebastien
AU - Mamessier, Emilie
AU - Pignon, Charles
AU - Hacein-Bey-Abina, Salima
AU - Malissen, Bernard
AU - Gut, Marta
AU - Gut, Ivo G.
AU - Dombret, Hervé
AU - MacIntyre, Elizabeth A.
AU - Howe, Steven J.
AU - Gaspar, H. Bobby
AU - Thrasher, Adrian J.
AU - Ifrah, Norbert
AU - Payet-Bornet, Dominique
AU - Duprez, Estelle
AU - Andrau, Jean Christophe
AU - Asnafi, Vahid
AU - Nadel, Bertrand
N1 - Publisher Copyright:
© 2015 Macmillan Publishers Limited. All rights reserved.
PY - 2015/2
Y1 - 2015/2
N2 - T-cell acute lymphoblastic leukaemias (T-ALL) are aggressive malignant proliferations characterized by high relapse rates and great genetic heterogeneity. TAL1 is amongst the most frequently deregulated oncogenes. Yet, over half of the TAL1 + cases lack TAL1 lesions, suggesting unrecognized (epi)genetic deregulation mechanisms. Here we show that TAL1 is normally silenced in the T-cell lineage, and that the polycomb H3K27me3-repressive mark is focally diminished in TAL1 + T-ALLs. Sequencing reveals that >20% of monoallelic TAL1 + patients without previously known alterations display microinsertions or RAG1/2-mediated episomal reintegration in a single site 5″ to TAL1. Using 'allelic-ChIP' and CrispR assays, we demonstrate that such insertions induce a selective switch from H3K27me3 to H3K27ac at the inserted but not the germline allele. We also show that, despite a considerable mechanistic diversity, the mode of oncogenic TAL1 activation, rather than expression levels, impact on clinical outcome. Altogether, these studies establish site-specific epigenetic desilencing as a mechanism of oncogenic activation.
AB - T-cell acute lymphoblastic leukaemias (T-ALL) are aggressive malignant proliferations characterized by high relapse rates and great genetic heterogeneity. TAL1 is amongst the most frequently deregulated oncogenes. Yet, over half of the TAL1 + cases lack TAL1 lesions, suggesting unrecognized (epi)genetic deregulation mechanisms. Here we show that TAL1 is normally silenced in the T-cell lineage, and that the polycomb H3K27me3-repressive mark is focally diminished in TAL1 + T-ALLs. Sequencing reveals that >20% of monoallelic TAL1 + patients without previously known alterations display microinsertions or RAG1/2-mediated episomal reintegration in a single site 5″ to TAL1. Using 'allelic-ChIP' and CrispR assays, we demonstrate that such insertions induce a selective switch from H3K27me3 to H3K27ac at the inserted but not the germline allele. We also show that, despite a considerable mechanistic diversity, the mode of oncogenic TAL1 activation, rather than expression levels, impact on clinical outcome. Altogether, these studies establish site-specific epigenetic desilencing as a mechanism of oncogenic activation.
UR - http://www.scopus.com/inward/record.url?scp=84923096527&partnerID=8YFLogxK
U2 - 10.1038/ncomms7094
DO - 10.1038/ncomms7094
M3 - Article
C2 - 25615415
AN - SCOPUS:84923096527
SN - 2041-1723
VL - 6
JO - Nature Communications
JF - Nature Communications
M1 - 6094
ER -